- Home
- TLS vs PRQR Comparison
TLS vs PRQR Comparison
Compare TLS & PRQR Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- TLS
- PRQR
- Stock Information
- Founded
- TLS 1969
- PRQR 2012
- Country
- TLS United States
- PRQR Netherlands
- Employees
- TLS N/A
- PRQR N/A
- Industry
- TLS EDP Services
- PRQR Biotechnology: Pharmaceutical Preparations
- Sector
- TLS Technology
- PRQR Health Care
- Exchange
- TLS Nasdaq
- PRQR Nasdaq
- Market Cap
- TLS 199.9M
- PRQR 179.1M
- IPO Year
- TLS 2020
- PRQR 2014
- Fundamental
- Price
- TLS $2.75
- PRQR $2.35
- Analyst Decision
- TLS Buy
- PRQR Strong Buy
- Analyst Count
- TLS 6
- PRQR 8
- Target Price
- TLS $3.94
- PRQR $8.88
- AVG Volume (30 Days)
- TLS 974.0K
- PRQR 357.1K
- Earning Date
- TLS 08-08-2025
- PRQR 08-07-2025
- Dividend Yield
- TLS N/A
- PRQR N/A
- EPS Growth
- TLS N/A
- PRQR N/A
- EPS
- TLS N/A
- PRQR N/A
- Revenue
- TLS $109,269,000.00
- PRQR $21,212,711.00
- Revenue This Year
- TLS $35.76
- PRQR N/A
- Revenue Next Year
- TLS $26.83
- PRQR N/A
- P/E Ratio
- TLS N/A
- PRQR N/A
- Revenue Growth
- TLS N/A
- PRQR 85.91
- 52 Week Low
- TLS $1.83
- PRQR $1.07
- 52 Week High
- TLS $4.82
- PRQR $4.62
- Technical
- Relative Strength Index (RSI)
- TLS 45.47
- PRQR 66.90
- Support Level
- TLS $3.01
- PRQR $2.10
- Resistance Level
- TLS $3.30
- PRQR $2.18
- Average True Range (ATR)
- TLS 0.21
- PRQR 0.13
- MACD
- TLS -0.02
- PRQR 0.01
- Stochastic Oscillator
- TLS 40.86
- PRQR 56.92
About TLS Telos Corporation
Telos Corp offers technologically forwarded, software-based security solutions that empower and protect the world's security-conscious organizations against rapidly evolving, sophisticated, and pervasive threats. Its business has two reportable and operating segments namely Security Solutions and Secure Networks. The Security Solutions segment focuses on cybersecurity, cloud, and identity solutions, and the Secure Networks focuses on enterprise security. The company derives maximum revenue from the Security Solutions segment.
About PRQR ProQR Therapeutics N.V.
ProQR Therapeutics NV is a biopharmaceutical company. It discovers and develops RNA therapeutics for patients with severe genetic rare diseases such as cystic fibrosis, Leber congenital amaurosis type 10, and dystrophic epidermolysis bullosa. The only reportable segment of the company is the discovery and development of different, RNA-based therapeutics.